Hansa Biopharma
Scheelevägen 22
SE-223 63 Lund, Sweden
Phone: +46 46 16 56 70

www.hansabiopharma.com

PRESS RELEASE

Hansa Biopharma to participate in Aktiespararna's Stora Aktiedagarna and SEB Healthcare Seminar 2026

Lund, Sweden, November 20, 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at Aktiespararna's "Stora Aktiedagarna" at 10:05 CET, and participating in a fireside chat at 11:30 CET at the SEB Healthcare Seminar 2026, both in Stockholm on Tuesday 24 November, 2026.

If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.

Event: Hansa Biopharma Corporate Presentation at "Stora Aktiedagarna"

Date, Time and Place: Tuesday 24 November, 10:05-10:30 CET, Stockholm

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

Webcast: https://invitepeople.com/public/events/abb1170de2/pages/adb0cf8149

Event: Fireside chat at SEB Healthcare Seminar 2026

Date, Time and Place: Tuesday 24 November, 11:30-12:10 CET, Stockholm

Moderator: Christopher Udhe, SEB, Senior Pharma & Biotech Equity Analyst

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

--- ENDS ---

Contacts for more information:

Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's

proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that is being developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix®, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.